Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Formulation 1 · AZD9550

Other · developed by ASTRAZENECA

Phase 1 Most advanced trial
AZN Developer

What is Formulation 1?

Formulation 1 (AZD9550) is a solution for injection given as a single subcutaneous injection. It is studied in healthy participants.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD9550
Drug type
Other
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Healthy Participants

More from ASTRAZENECA

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Formulation 1

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.